Download PDF
Thromb Haemost 2002; 87(06): 928-929
DOI: 10.1055/s-0037-1613113
Commentary
Schattauer GmbH

Blood Clotting Activation, Angiogenesis and Tumor Metastasis: Any Role for TFPI?

Roberto Lorenzet
2   “A. Taticchi” Unit of Atherosclerosis and Thrombosis, Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy
,
Maria Benedetta Donati
1   Research and Training Center, Catholic University, Campobasso, Italy
› Author Affiliations
Further Information

Publication History

Received 02 April 2002

Accepted 02 April 2002

Publication Date:
08 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Rickles FR, Levine MN. Venous thromboembolism in malignancy and malignancy in venous thromboembolism. Haemostasis 1998; 28 (Suppl. 03) 43-9.
    PubMedGoogle Scholar
  • 2 Falanga A, Donati MB. Pathogenesis of thrombosis in patients with malignancy. Int J Hematol 2001; 73: 137-44.
    CrossrefPubMedGoogle Scholar
  • 3 Donati MB, Semeraro N. Cancer cell procoagulants and their pharmacological modulation. Haemostasis 1984; 14: 422-9.
    PubMedGoogle Scholar
  • 4 Colucci M, Balconi G, Lorenzet R, Pietra A, Locati D, Donati MB, Semeraro N. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983; 71: 1893-6.
    CrossrefPubMedGoogle Scholar
  • 5 Napoleone E, Di Santo A, Lorenzet R. Monocytes upregulate endothelial cell expression of tissue factor: a role for cell-cell contact and cross-talk. Blood 1997; 89: 541-9.
    PubMedGoogle Scholar
  • 6 Lorenzet R, Napoleone E, Celi A, Pellegrini G, Di Santo AM. Cell-cell interaction and tissue factor expression. Blood Coagul Fibrinol 1998; 09 (Suppl. 01) S49-S59.
    PubMedGoogle Scholar
  • 7 Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry 1985; 24: 5558-67.
    CrossrefPubMedGoogle Scholar
  • 8 Falanga A, Alessio MG, Donati MB, Barbui T. A new procoagulant in acute leukemia. Blood 1988; 71: 870-5.
    PubMedGoogle Scholar
  • 9 Donati MB, Gambacorti-Passerini C, Casali B, Falanga A, Vannotti P, Fossati G, Semeraro N, Gordon SG. Cancer procoagulant in human tumor cells: evidence from melanoma patients. Cancer Res 1986; 46 (12 Pt 1) 6471-4.
    PubMedGoogle Scholar
  • 10 Lorenzet R, Peri G, Locati D, Allavena P, Colucci M, Semeraro N, Mantovani A, Donati MB. Generation of procoagulant activity by mononuclear phagocytes: a possible mechanism contributing to blood clotting activation within malignant tissues. Blood 1983; 62: 271-3.
    PubMedGoogle Scholar
  • 11 Rambaldi A, Alessio G, Casali B, Gambacorti-Passerini C, Donati MB, Mantovani A, Semeraro N. Induction of monocyte-macrophage procoagulant activity by transformed cell lines. J Immunol 1986; 136 (10) 3848-55.
    PubMedGoogle Scholar
  • 12 Falanga A, Marchetti M, Giovanelli S, Barbui T. All-trans-retinoic acid counteracts endothelial cell procoagulant activity induced by a human promyelocytic leukemia-derived cell line (NB4). Blood 1996; 87 (02) 613-7.
    PubMedGoogle Scholar
  • 13 Colucci M, Giavazzi R, Alessandri G, Semeraro N, Mantovani A, Donati MB. Procoagulant activity of sarcoma sublines with different metastatic potential. Blood 1981; 57: 733-5.
    PubMedGoogle Scholar
  • 14 Bromberg ME, Konisberg WH, Madison JF, Pawashe A, Goren A. Tissue factor promotes melanoma metastases by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995; 92: 8205-9.
    CrossrefPubMedGoogle Scholar
  • 15 Contrino J, Hair GA, Schmeizl MA, Rickles FR, Kreutzer DL. In situ characterization of antigenic and functional tissue factor expression in human tumors utilizing monoclonal antibodies and recombinant factor VIIa as probes. Am J Pathol 1994; 145 (06) 1315-22.
    PubMedGoogle Scholar
  • 16 Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 1992; 89: 11832-6.
    CrossrefPubMedGoogle Scholar
  • 17 Mueller BM, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest 1998; 101: 1372-8.
    CrossrefPubMedGoogle Scholar
  • 18 Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease. Nature Med 1996; 02: 209-15.
    CrossrefPubMedGoogle Scholar
  • 19 Colucci M, Delaini F, de Bellis GVitti, Locati D, Poggi A, Semeraro N, Donati MB. Warfarin inhibits both procoagulant activity and metastatic capacity of Lewis lung carcinoma cells. Role of vitamin K deficiency. Biochem Pharmacol 1983; 32 (11) 1689-91.
    CrossrefPubMedGoogle Scholar
  • 20 Ornstein DL, Zacharski LR. Treatment of cancer with anticoagulants: rationale in the treatment of melanoma. Int J Hematol 2001; 73 (02) 157-61.
    CrossrefPubMedGoogle Scholar
  • 21 Broze Jr GJ. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinol 1995; (Suppl. 01) S7-S13.
    PubMedGoogle Scholar
  • 22 Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001; 86: 959-72.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 de Jonge E, Dekkers PEP, Creasey AA, Hack CE, Paulson SK, Karim A, Kesecioglu J, Levi M, van Deventer SJH, van der Poll T. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000; 95: 1124-9.
    PubMedGoogle Scholar
  • 24 Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med 2000; 28 (Suppl.): S31-S33.
    CrossrefPubMedGoogle Scholar
  • 25 Donati MB. Cancer and thrombosis: from phlegmasia alba dolens to transgenic mice. Thromb Haemost 1995; 74: 278-81.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Fischer EG, Riewald M, Huang HY, Miyagi Y, Kubota Y, Mueller BM, Ruf W. Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor. J Clin Invest 1999; 104 (09) 1213-21.
    CrossrefPubMedGoogle Scholar